Investment Thesis
Petros Pharmaceuticals exhibits severe operational distress with -$5.8M operating cash flow against only $203.7K in revenue, indicating an unsustainable business model. Positive net income appears driven by non-operating items rather than core operations, while cash burn at current rates provides only ~1 year of runway. Fundamental viability is highly questionable for a pharmaceutical company with negligible revenue and persistent operational losses.
Strengths
- Strong liquidity position with 2.22x current ratio and adequate cash reserves of $6.1M
- Moderate debt levels with 0.52x debt-to-equity ratio and manageable leverage
- Exceptional revenue growth rate of 1275% YoY, though from negligible base
Risks
- Critical cash burn: -$5.8M operating cash flow against $6.1M total cash provides ~1 year runway at current rates
- Severe operational losses of -$4.2M on $203.7K revenue with -2086.8% operating margin indicating non-viable business model
- Profitability metrics appear distorted by non-operating gains; negative EPS contradicts positive net income, suggesting earnings quality issues and potential accounting irregularities
- Negligible revenue base insufficient to support pharmaceutical R&D and operations; likely shell company or pre-revenue biotech
- No insider buying activity in 90 days suggests lack of management confidence
Key Metrics to Watch
- Operating cash flow trend - company must achieve cash flow break-even before reserves deplete
- Revenue trajectory - current base of $203.7K is insufficient; must scale significantly or shut down
- Cash burn rate and remaining runway - critical survival metric given operational losses
Financial Metrics
Revenue
203.7K
Net Income
2.3M
EPS (Diluted)
$-1.95
Free Cash Flow
-5.8M
Total Assets
6.1M
Cash
6.1M
Profitability Ratios
Gross Margin
1,914.7%
Operating Margin
-2,086.8%
Net Margin
1,104.9%
ROE
66.8%
ROA
36.7%
FCF Margin
-2,860.6%
Balance Sheet & Liquidity
Current Ratio
2.22x
Quick Ratio
1.73x
Debt/Equity
0.52x
Debt/Assets
45.1%
Interest Coverage
-7.58x
Long-term Debt
1.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T18:30:23.656839 |
Data as of: 2025-09-30 |
Powered by Claude AI